Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB.

IF 1.4 4区医学 Q4 INFECTIOUS DISEASES

Journal of Infection in Developing Countries Pub Date : 2024-07-29 DOI:10.3855/jidc.18887

Di Liu, Fang Jie, Yongjie Ding, Hongping Qu, Dechang Chen, Jie Huang

{"title":"Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB.","authors":"Di Liu, Fang Jie, Yongjie Ding, Hongping Qu, Dechang Chen, Jie Huang","doi":"10.3855/jidc.18887","DOIUrl":null,"url":null,"abstract":"Introduction: The aim of this study was to compare the efficacy and safety of colistin sulfate (CS) with polymyxin B sulfate (PMB) in the treatment of pneumonia induced by carbapenem-resistant Gram-negative bacteria (CR-GNB).Methodology: Patients diagnosed with pneumonia caused by CR-GNB and admitted to the intensive care unit (ICU) from January 2020 to September 2022 were enrolled in this study. The patients were divided into the CS group and the PMB group according to their medication regimens. Group-wise demographic data, clinical efficacy, prognosis, and adverse events were analyzed and compared.Results: A total of 120 patients (68 in the CS group and 52 in the PMB group) with pneumonia were included in the study. The majority of the pathogens were CR-Acinetobacter baumannii, followed by CR-Klebsiella pneumoniae, and CR-Pseudomonas aeruginosa. The clinical response rates in the CS and PMB groups after treatment were 62.0% and 65.4%, bacterial clearances were 44.0% and 36.5%, 28-day mortality rates were 16.0% and 13.5%, respectively; no significant differences between the two treatments were found. Nevertheless, the adverse effects were significantly less common in the CS group than in the PMB group, especially when treatments were administered intravenously.Conclusions: CS, a novel polymyxin E formulation, is as effective as PMB in treating pneumonia induced by CR-GNB while causing less side effects.","PeriodicalId":49160,"journal":{"name":"Journal of Infection in Developing Countries","volume":"18 7","pages":"1050-1057"},"PeriodicalIF":1.4000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection in Developing Countries","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3855/jidc.18887","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The aim of this study was to compare the efficacy and safety of colistin sulfate (CS) with polymyxin B sulfate (PMB) in the treatment of pneumonia induced by carbapenem-resistant Gram-negative bacteria (CR-GNB).

Methodology: Patients diagnosed with pneumonia caused by CR-GNB and admitted to the intensive care unit (ICU) from January 2020 to September 2022 were enrolled in this study. The patients were divided into the CS group and the PMB group according to their medication regimens. Group-wise demographic data, clinical efficacy, prognosis, and adverse events were analyzed and compared.

Results: A total of 120 patients (68 in the CS group and 52 in the PMB group) with pneumonia were included in the study. The majority of the pathogens were CR-Acinetobacter baumannii, followed by CR-Klebsiella pneumoniae, and CR-Pseudomonas aeruginosa. The clinical response rates in the CS and PMB groups after treatment were 62.0% and 65.4%, bacterial clearances were 44.0% and 36.5%, 28-day mortality rates were 16.0% and 13.5%, respectively; no significant differences between the two treatments were found. Nevertheless, the adverse effects were significantly less common in the CS group than in the PMB group, especially when treatments were administered intravenously.

Conclusions: CS, a novel polymyxin E formulation, is as effective as PMB in treating pneumonia induced by CR-GNB while causing less side effects.

查看原文本刊更多论文

硫酸可乐定和硫酸多粘菌素 B 治疗 CR-GNB 引发的肺炎效果的真实世界数据。

简介本研究旨在比较硫酸可乐定（CS）和硫酸多粘菌素B（PMB）治疗耐碳青霉烯革兰阴性菌（CR-GNB）引起的肺炎的有效性和安全性：研究对象： 2020年1月至2022年9月期间，重症监护室（ICU）收治的由耐碳青霉烯革兰阴性菌（CR-GNB）引起的肺炎患者。根据用药方案将患者分为 CS 组和 PMB 组。对各组的人口统计学数据、临床疗效、预后和不良事件进行了分析和比较：研究共纳入了 120 名肺炎患者（CS 组 68 人，PMB 组 52 人）。大多数病原体为CR-鲍曼不动杆菌，其次是CR-肺炎克雷伯菌和CR-铜绿假单胞菌。CS组和PMB组治疗后的临床应答率分别为62.0%和65.4%，细菌清除率分别为44.0%和36.5%，28天死亡率分别为16.0%和13.5%；两种治疗方法之间没有发现显著差异。然而，CS组的不良反应明显少于PMB组，尤其是在静脉注射治疗时：结论：CS 是一种新型多粘菌素 E 制剂，在治疗 CR-GNB 引起的肺炎方面与 PMB 一样有效，但副作用较小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infection in Developing Countries INFECTIOUS DISEASES-

CiteScore

3.70

自引率

5.30%

发文量

239

审稿时长

4-8 weeks

期刊介绍： The Journal of Infection in Developing Countries (JIDC) is an international journal, intended for the publication of scientific articles from Developing Countries by scientists from Developing Countries. JIDC is an independent, on-line publication with an international editorial board. JIDC is open access with no cost to view or download articles and reasonable cost for publication of research artcles, making JIDC easily availiable to scientists from resource restricted regions.